Isa Lucet

Lab Head Chemical Biology @WEHI_research | Structural Biologist shedding invisible 🫥 light on (Pseudo)Kinases|Drug Discovery | Promoting STEM Leadership

[Isa Lucet @Isa_Lucet]

Absolutely thrilled to see ProteinDJ released. Many thanks to @joshuamhardy Dylan Silke and the team Junqi Pan, Andrew Thompson, Julie Iskander, @TonyPapenfuss for their enormous amount of work, making this pipeline open source.

[Josh Hardy @joshuamhardy]

I am thrilled to release ProteinDJ: a high-performance and modular protein design pipeline. Our open-source workflow incorporates #RFdiffusion, #ProteinMPNN, #FAMPNN, #AlphaFold2 and #Boltz-2. It is a fast, free, and fun way to design proteins (1/5)
https://t.co/IOlC0JKvOL

[Isa Lucet @Isa_Lucet]

Proud of the @Isa_Lucet team from @WEHI_research , Emily park @CCeMMP , Lyn Deng , Dylan Silke, Jean-Max Mazeri, @joshuamhardy & andrew thompson, showcasing their latest research, everything Ephrin receptors, DCLK1 & Protein DJ synthetic binders at @LorneProteins.

[Isa Lucet @Isa_Lucet]

@ONJCRI @scisignal @latrobe Excited to see this DCLK1 study published, a collaborative work @latrobe with Michael Buchert and team that started many years ago, reinforcing our efforts in developing @WEHI_research, @Isa_Lucet, bespoke DCLK1-based diagnostics &therapeutics. Congratulations to all.

[ONJ Cancer Research Institute @ONJCRI]

💫 Our new publication in @scisignal reveals insights into gastric cancer progression! Funded by @latrobe, Dr Shoukat Sterle & team found inhibiting DCLK1 reduces tumour growth and prevents cancer from reshaping its environment.

Congrats to the team!
👉 https://t.co/L938JsYJz3

[James Murphy @pseudokinase]

Awesome to see this fantastic study of the elusive EphB6 pseudokinase in print at long last https://t.co/jrI6AqZ1xL
Massive congrats to star PhD student @LungYu_Liang (now in Frankfurt) who bravely took on this toughest of projects with @Isa_Lucet and me

[Isa Lucet @Isa_Lucet]

Many thanks to @KRogers1001 and her team @geogphotog Mike M, Lacklan W and to @DebnathGhosal and Andrew Leis for their dedicated support and to all others. Thanks to @nhmrc , Melbourne Research Scholarship and @WEHI_research for funding.

[James Murphy @pseudokinase]

Awesome to see this fantastic study of the elusive EphB6 pseudokinase in print at long last https://t.co/jrI6AqZ1xL
Massive congrats to star PhD student @LungYu_Liang (now in Frankfurt) who bravely took on this toughest of projects with @Isa_Lucet and me

[Isa Lucet @Isa_Lucet]

Thrilled about our latest Pseudokinase research published today in @CommsBio, showing EphB6 power in promoting cell cell adhesion through formation of intercellular tubes. Many congratulations to our star PhD student @LungYu_Liang.

[James Murphy @pseudokinase]

Awesome to see this fantastic study of the elusive EphB6 pseudokinase in print at long last https://t.co/jrI6AqZ1xL
Massive congrats to star PhD student @LungYu_Liang (now in Frankfurt) who bravely took on this toughest of projects with @Isa_Lucet and me

[Charles Bayly-Jones @bj_charles]

@joshuamhardy hey mate, I enjoyed your talk. TEMPO is a taking off! A really great initiative. If we can, Monash should contribute more material or content, whatever helps. Keep it up 🤘

[ARC CCeMMP @CCeMMP]

@CCeMMP group photo of centre members/affiliates at #cryoz23 - a great turn out in Brisbane! And thanks to outreach committee members for coordinating our 'macromolecular' assembly photoshoot 😀 @arc_gov_au #croEM #croET (credits to @LouBrillault for the photo).

[Josh Hardy @joshuamhardy]

ARC CCeMMP members enjoying a lunch break during the CRYOZ23 cryo-EM workshops. We've been learning cryo-electron tomography, modelling, and image analysis. @CCeMMP @UQ_SCMB

[The Florey @TheFlorey]

Calling scientists and chemists in Melbourne 🧑���🔬

Coming all the way from Copenhagen, Prof Meldal will *next week* present his Nobel Prize-winning work in 'click chemistry' work to the scientific community in Parkville 🧪

Register your attendance here: https://t.co/vRyWAFztQa

[Isa Lucet @Isa_Lucet]

@purton_louise @pseudokinase @dr_opatel Let’s also hope for a cultural shift in Australia’s academia-industry funding landscape, enabling a better recognition of academic researchers dedicating their research towards advancing the discovery of therapeutic drugs!

[Isa Lucet @Isa_Lucet]

@dr_opatel @pseudokinase Thanks James. Yes a long road. Increasing drastically the funding for multidisciplinary basic science, including Structural Biology, Chemical Biology and Chemistry is so critical for Australia to remain internationally competitive.

[Isa Lucet @Isa_Lucet]

@purton_louise @dr_opatel Thank you Louise for your great support, advocating for #WomenInSTEM. Much appreciated.

[Isa Lucet @Isa_Lucet]

@WEHI_research @dr_opatel @MonashUni Privileged to have had the opportunity to contribute to such an impactful research program as a NHMRC Industry Fellow back in the days. Many thanks also to @WEHI_research for their continued support in kinase drug discovery over the past decade.

[WEHI (Walter and Eliza Hall Institute) @WEHI_research]

A fantastic achievement for a home-grown Australian discovery. Congrats to WEHI #structuralbiologists, @Isa_Lucet @dr_opatel for their contribution to structure-based #drugdiscovery of #momelotinib during their time at @MonashUni in partnership with Cytopia. #WomenInScience

[Demis Hassabis @demishassabis]

Excited to share #AlphaMissense our new AI system that can classify whether genetic mutations (missense variants) are benign or harmful - a critical step toward uncovering causes of many diseases, from cystic fibrosis to cancer. In @ScienceMagazine today https://t.co/pIsskIe1cP

[Isa Lucet @Isa_Lucet]

A shining example of innovation, showcasing the power of integrating structural biology in early drug discovery and academia/industry partnership. Kudos to the incredible teams at Monash & Cytopia. Special shoutout to the many women involved #WomenInScience

[Isa Lucet @Isa_Lucet]

@dr_opatel @kyra_gillespie @ausmedchemist @US_FDA Same for me

[Amplia Therapeutics @ampliatx]

In exciting news for Australian biotech this week, momelotinib, a drug co-invented in Melbourne by Amplia CEO, Dr Chris Burns, has been granted approval by the FDA for the treatment of myelofibrosis. Read more: https://t.co/fK7AF74pKT $ATX #biotech #innovation #FDA #drugdiscovery